×
News Home

Is Adaptimmune Therapeutics PLC - ADR (ADAP) Stock a Bad Value Thursday?

Thursday, December 02, 2021 11:48 AM | InvestorsObserver Analysts
Is Adaptimmune Therapeutics PLC - ADR (ADAP) Stock a Bad Value Thursday?

A rating of 83 puts Adaptimmune Therapeutics PLC - ADR (ADAP) near the top of the Healthcare sector according to InvestorsObserver. Adaptimmune Therapeutics PLC - ADR's score of 83 means that it ranks higher than 83% of stocks in the sector. In addition, its overall score of 13 ranks it higher than 13% of all stocks.

Overall Score - 13
ADAP has an Overall Score of 13. Find out what this means to you and get the rest of the rankings on ADAP!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. *Investors Observer* allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 13 would rank higher than 13 percent of all stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in the healthcare sector with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Adaptimmune Therapeutics PLC - ADR Stock Today?

Adaptimmune Therapeutics PLC - ADR (ADAP) stock is unmoved -0.08% while the S&P 500 is up 0.9% as of 11:46 AM on Thursday, Dec 2. ADAP is unmoved $0.00 from the previous closing price of $3.70 on volume of 1,005,852 shares. Over the past year the S&P 500 is higher by 24.11% while ADAP has fallen -18.68%. ADAP lost -$1.00 per share the over the last 12 months. Click Here to get the full Stock Report for Adaptimmune Therapeutics PLC - ADR stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App